About Us

Warnex is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors.

Warnex Analytical Services provides a variety of quality control services, including traditional chemistry, microbiology, chromatography and stability testing, as well as method development and validation, to clients in the pharmaceutical and biotechnology industries.

Warnex Bioanalytical Services conducts bioavailability and bioequivalence studies for clinical trials, and performs contract R&D for clients in the pharmaceutical and biotechnology industries.

Warnex Medical Laboratories provides specialized genetic and biochemical testing for the healthcare industry, including the Prenatest® prenatal screening test for Down syndrome (trisomy 21), trisomy 18 and other chromosomal anomalies. This division also has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

Until the last quarter of 2006, Warnex was also focused on the research, development, production and distribution of DNA-based quality control products for the agri-food industry. The Company decided to divest of this business since it required a global distribution platform, a wider product offering and additional funding to achieve its full commercial potential. The assets of this division were sold, effective June 28, 2007.

Warnex was founded on and remains committed to a business philosophy that reduces risk while building long-term shareholder value. Our goal is to grow our laboratory services divisions both organically and through acquisitions. Our analytical, bioanalytical and medical laboratory divisions have generated a strong 5-year compound annual revenue growth rate of 31% along with ongoing profitability.

The Company’s shares are traded on the Toronto Stock Exchange (TSX) under the symbol WNX.